Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma

View through CrossRef
Background 131I-meta-iodo-benzylguanidine (131I-mIBG) therapy has been used in treatment of for advanced neuroblastoma for many years with promising results. There are several studies regarding predictors and outcomes of 131I-mIBG therapies in relapsed/refractory neuroblastoma patients. Objective To identify the predictors and outcomes of 131I-mIBG treatment in relapsed/refractory neuroblastoma. Methods This study was a retrospective review of 22 patients with high risk stage IV relapsed/refractory neuroblastoma who received at least one cycle of 131I-mIBG therapy. Patient’ characteristics, hematologic toxicity, scintigraphic semi-quantitative scoring, and overall survival were recorded. Factors predicting survival were analyzed. Results Twenty-two patients (50% male) with mean age of 3.7 years (4.8 months to 8.3 years) received 131I-mIBG therapies at an average of 3.8 and mean dose of 136 mCi (5032 MBq) per treatment. Most common acute hematologic toxicity was thrombocytopenia. Overall 5-year survival rate was 37% (95% confidence interval: 16.3–58.0) and median survival time was 2.8 year (95% confidence interval: 1.38–6.34). Patients with rising Curie score of ≥25% upon the second therapy were major determinants of overall survival with poorer response to treatment. At least three treatments of 131I-mIBG were needed to identify some degrees of survival prolongation (crude hazard ratio: P-value = 0.003). Age, sex, metastatic status, and baseline Curie scoring system were good predictors associated with survival. Seven patients (32%) demonstrated objective responses. Conclusion Despite multimodality therapy, high risk neuroblastoma had a propensity of treatment failure in terms of relapsed or refractory, with some objective responses after 131I-mIBG treatments. The declined or non-rising Curie score upon second post-treatment total body scan was an important predictor of survival and aided a decision whether or not to proceed with bone marrow transplantation.
Title: Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma
Description:
Background 131I-meta-iodo-benzylguanidine (131I-mIBG) therapy has been used in treatment of for advanced neuroblastoma for many years with promising results.
There are several studies regarding predictors and outcomes of 131I-mIBG therapies in relapsed/refractory neuroblastoma patients.
Objective To identify the predictors and outcomes of 131I-mIBG treatment in relapsed/refractory neuroblastoma.
Methods This study was a retrospective review of 22 patients with high risk stage IV relapsed/refractory neuroblastoma who received at least one cycle of 131I-mIBG therapy.
Patient’ characteristics, hematologic toxicity, scintigraphic semi-quantitative scoring, and overall survival were recorded.
Factors predicting survival were analyzed.
Results Twenty-two patients (50% male) with mean age of 3.
7 years (4.
8 months to 8.
3 years) received 131I-mIBG therapies at an average of 3.
8 and mean dose of 136 mCi (5032 MBq) per treatment.
Most common acute hematologic toxicity was thrombocytopenia.
Overall 5-year survival rate was 37% (95% confidence interval: 16.
3–58.
0) and median survival time was 2.
8 year (95% confidence interval: 1.
38–6.
34).
Patients with rising Curie score of ≥25% upon the second therapy were major determinants of overall survival with poorer response to treatment.
At least three treatments of 131I-mIBG were needed to identify some degrees of survival prolongation (crude hazard ratio: P-value = 0.
003).
Age, sex, metastatic status, and baseline Curie scoring system were good predictors associated with survival.
Seven patients (32%) demonstrated objective responses.
Conclusion Despite multimodality therapy, high risk neuroblastoma had a propensity of treatment failure in terms of relapsed or refractory, with some objective responses after 131I-mIBG treatments.
The declined or non-rising Curie score upon second post-treatment total body scan was an important predictor of survival and aided a decision whether or not to proceed with bone marrow transplantation.

Related Results

Prediction of 131I Uptake in Lung Metastases of Differentiated Thyroid Cancer Using Deep Learning
Prediction of 131I Uptake in Lung Metastases of Differentiated Thyroid Cancer Using Deep Learning
Abstract Objective: An accurate assessment the 131I accumulation capacity in lung metastases of differentiated thyroid cancer (DTC) is pivotal to inform radioiodine therapy...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Urinary iodine concentration: a biochemical parameter for assessing the iodine status
Urinary iodine concentration: a biochemical parameter for assessing the iodine status
Iodine is a micronutrient, which is essential for the synthesis of thyroid hormones. Thyroid hormones play a major role in the development of different functional components in dif...
Monitoring the Efficacy of Iodine‐131‐MIBG Therapy using Fluorine‐18‐FDG‐PET
Monitoring the Efficacy of Iodine‐131‐MIBG Therapy using Fluorine‐18‐FDG‐PET
Summary: Background: The purpose of this study was to assess the potential of fluorine‐18 fluoro‐2‐deoxy‐d‐glucose positron emission tomography (18F‐FDG‐PET) for monitoring the eff...
Diagnostic Accuracy of WB-MRI and 123I-mIBG /131I-mIBG Imaging in Metastatic Pheochromocytoma and Paraganglioma: A Comparative Study
Diagnostic Accuracy of WB-MRI and 123I-mIBG /131I-mIBG Imaging in Metastatic Pheochromocytoma and Paraganglioma: A Comparative Study
Abstract Purpose This study aimed to compare tumor lesion detectability and diagnostic accuracy of whole-body magnetic resonance imaging (WB-MRI) and radioiodine-labeled m...
Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma
Evaluating the diagnostic efficacy of whole-body MRI versus 123I-mIBG/131I-mIBG imaging in metastatic pheochromocytoma and paraganglioma
AbstractThis study aimed to compare tumor lesion detectability and diagnostic accuracy of whole-body magnetic resonance imaging (WB-MRI) and radioiodine-labeled meta-iodo-benzylgua...

Back to Top